Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.50
-0.26 (-4.51%)
At close: May 14, 2026, 4:00 PM EDT
5.51
+0.01 (0.18%)
After-hours: May 14, 2026, 6:35 PM EDT

Lexeo Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-87.5-99.96-98.33-66.39-59.28-50.62
Depreciation & Amortization
0.280.270.30.270.120.01
Stock-Based Compensation
11.1912.1312.473.041.780.39
Other Adjustments
0.19-1.491.682.11.03-
Changes in Accounts Payable
-8.3-1.562.38-0.18-0.433.02
Changes in Accrued Expenses
-7.85-4.453.372.094.483.4
Changes in Income Taxes Payable
-----0.020.49
Changes in Unearned Revenue
-----0.05-0.09
Changes in Other Operating Activities
-4.3-3.51-3.02-0.43-2.19-0.77
Operating Cash Flow
-97.99-98.56-81.15-59.5-54.56-44.18
Capital Expenditures
-0.43-0.4-0.48-0.12-0.67-0.19
Purchases of Intangible Assets
----0.05-0.23-
Purchases of Investments
-167.7-195.38-93.6---
Proceeds from Sale of Investments
117.42105.53----
Investing Cash Flow
-78.39-90.25-94.08-0.17-0.9-0.19
Long-Term Debt Issued
---4--
Net Long-Term Debt Issued (Repaid)
---4--
Issuance of Common Stock
42.76234.0895.49100.30.330.17
Repurchase of Common Stock
---0.02---
Net Common Stock Issued (Repurchased)
42.76234.0895.47100.30.330.17
Issuance of Preferred Stock
----0.02151.06
Net Preferred Stock Issued (Repurchased)
----0.02151.06
Other Financing Activities
-3.98-17.28-6.7-0.51-0.16-0.37
Financing Cash Flow
219.24216.888.78103.790.19150.86
Net Cash Flow
42.8627.98-86.4544.13-55.27106.49
Free Cash Flow
-98.42-98.96-81.63-59.61-55.23-44.37
FCF Margin
-----8445.26%-2677.73%
Free Cash Flow Per Share
-1.50-1.84-2.57-11.13-33.88-28.58
Levered Free Cash Flow
-108.1-109.61-95.78-60.76-58.04-44.76
Unlevered Free Cash Flow
-118.39-118.9-103.21-66.88-59.27-44.77
Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q